輸血診断市場の2030年までの予測：製品別、用途別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界の輸血診断市場は2023年に48億米ドルを占め、予測期間中のCAGRは8.5％で成長し、2030年には85億米ドルに達すると予測されています。

同市場は、感染症の検出、血液型の特定、ドナーとレシピエント間の適合性評価により、輸血の安全性と有効性を確保する上で重要な役割を果たしています。これらの診断薬は、HIV、B型肝炎、C型肝炎、梅毒などの潜在的な病原体の特定に役立ち、輸血によって感染するリスクを低減します。さらに、血液型検査とクロスマッチング検査は、ドナーとレシピエントの血液の適合性を保証し、輸血中の副作用の可能性を最小限に抑えます。

2022年3月にMedscapeが発表した記事によると、米国における血友病Aの有病率は男性10万人当たり20.6人であると報告されています。カナダ血友病協会（CHS）が2022年2月に発表した記事によると、血友病AおよびBに罹患しているカナダ人の総数は3,100人と推定されています。

献血者スクリーニングプログラムの増加

公衆衛生と安全基準がますます重視される中、献血された血液の完全性を損なう可能性のある感染症やその他の健康状態を検出することを目的とした献血者スクリーニングプログラムが普及しています。これらのスクリーニング・プログラムは、核酸検査（NAT）、血清学的検査、免疫測定法などの高度な診断技術を採用し、献血に関連する潜在的なリスクを特定することで、輸血によって感染する可能性を最小限に抑えています。

高額な機器と検査費用

輸血診断学は、輸血用として提供された血液の安全性と適合性を確保するために、専門的な機器と高度な検査に大きく依存しています。自動分析装置から試薬や消耗品に至るまで、これらのツールは調達やメンテナンスに多額の費用がかかります。診断手順が複雑なため、操作と解釈には熟練した人材が必要となり、全体的なコストはさらに膨らみます。しかし、特に資源に乏しい環境や発展途上国のヘルスケア施設にとって、このような機器への投資や検査の実施にかかる経済的負担は莫大なものとなり、包括的な輸血サービスの提供能力が制限される可能性があります。

ヘルスケア支出の増加

ヘルスケア支出の増加に伴い、輸血診断を含む高度な医療技術や処置に対する需要も増加しています。このような支出の増加により、ヘルスケア施設は輸血の安全性と有効性を確保するために最先端の機器や診断ツールに投資することができます。さらに、医療予算が拡大するにつれて、患者の転帰を改善し、輸血感染症や副作用など輸血に関連するリスクを軽減することが重視されるようになっています。

先端技術へのアクセス制限

正確で効率的な輸血診断には、核酸増幅検査（NAT）、次世代シークエンシング（NGS）、自動血液スクリーニングシステムなどの最先端技術へのアクセスが不可欠です。多くの地域、特に発展途上国や遠隔地では、ヘルスケア施設にこれらの先端技術を導入するためのインフラ、リソース、訓練された人材が不足している場合があります。その結果、タイムリーで正確な血液スクリーニングと適合性試験を実施する能力が損なわれ、輸血感染症や不適合輸血などの潜在的なリスクにつながる可能性があります。

COVID-19の影響：

重篤な呼吸困難や輸血支援を必要とするその他の重篤な状態など、コビッド関連の合併症により輸血の需要が増加しました。この需要の急増は、血液製剤の安全性と適合性を確保するための診断サービスを圧迫しました。一方、パンデミックに関連した規制、感染症への恐怖、ヘルスケアサービスの混乱は献血の減少につながり、血液サプライチェーンに影響を与えました。その結果、輸血診断企業は適切な在庫レベルを維持し、献血された血液をタイムリーに検査するという課題に直面し、パンデミックの不確実性の中で輸血の安全を守るための効率的な診断ソリューションと技術の必要性が高まっています。

予測期間中、ヘモグロビン濃度計セグメントが最大になる見込み

ヘモグロビン濃度計は、ヘモグロビン濃度の迅速かつ信頼性の高い評価を提供し、献血者のスクリーニングを支援し、輸血の安全性と有効性を確保することから、予測期間中、ヘモグロビン濃度計セグメントは最大になると予想されます。ヘルスケア専門家がヘモグロビン濃度を迅速に測定できるようにすることで、ヘモグロビン濃度計は献血プロセスを合理化し、輸血反応のリスクを低減し、患者の転帰全体を改善します。さらに、これらの機器は持ち運びが可能で使い勝手が良いため、遠隔地や資源が限られた地域を含む様々なヘルスケア環境で利用することができます。

予測期間中、CAGRが最も高くなると予想されるのは血液型分類セグメントです。

血液型分類分野は、予測期間中に最も高いCAGRが見込まれます。正確な血液型分類とクロスマッチングは、輸血時の副作用を防ぐために非常に重要です。自動化システムや分子検査法のイントロダクションなど、血液型分類に関する技術や手法の進歩により、ヘルスケア施設は効率的に血液型を決定し、不規則な抗体をスクリーニングできるようになった。これにより、輸血反応のリスクが大幅に減少し、患者の転帰が改善されました。さらに、外科手術の増加、外傷症例、慢性疾患による血液製剤の需要増加が、輸血診断市場の地域別成長をさらに促進しています。

最大のシェアを占める地域

可処分所得の増加、医療インフラの改善、健康意識の高まり、有利な償還政策により、予測期間中、北米地域が最大のシェアを占めました。米国赤十字社は、米国では年間1,600万個の血液成分が輸血されていると推定しています。さらに、この地域の輸血感染率の高さと献血意識の高まりが、市場拡大に拍車をかけると予測されています。

CAGRが最も高い地域：

治療のために赤血球輸血を必要とする貧血患者が増加していることから、アジア太平洋地域は長期にわたって持続的な成長を遂げると予測され、輸血診断薬の需要を押し上げると予想されます。この地域では、血友病、がん、血小板減少症などの血液関連疾患や慢性腎臓病（CKD）の有病率が上昇しているため、血液製剤や輸血全体の需要が高いです。

無料のカスタマイズ提供：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• 用途分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の輸血診断市場：製品別

• ヘモグロビン計
• 機器
• プラズマ
• 試薬とキット
• その他の製品

第6章 世界の輸血診断市場：用途別

• 病気のスクリーニング
  • 分子疾患スクリーニング
  • 血清学的疾患のスクリーニング
• 血液型分類
• その他の用途

第7章 世界の輸血診断市場：エンドユーザー別

• 診断研究所
• 病院
• その他のエンドユーザー

第8章 世界の輸血診断市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Abbott Laboratories
• BAG Healthcare GmBH
• Bio-Rad Laboratories, Inc
• Danaher Corporation
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd
• Grifols S.A.
• Hologic, Inc
• Immucor, Inc
• Ortho Clinical Diagnostics
• Siemens Healthcare Private Limited

List of Tables

• Table 1 Global Blood Transfusion Diagnostics Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Blood Transfusion Diagnostics Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Blood Transfusion Diagnostics Market Outlook, By Hemoglobinometers (2021-2030) ($MN)
• Table 4 Global Blood Transfusion Diagnostics Market Outlook, By Instruments (2021-2030) ($MN)
• Table 5 Global Blood Transfusion Diagnostics Market Outlook, By Plasma (2021-2030) ($MN)
• Table 6 Global Blood Transfusion Diagnostics Market Outlook, By Reagents & kits (2021-2030) ($MN)
• Table 7 Global Blood Transfusion Diagnostics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 8 Global Blood Transfusion Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 9 Global Blood Transfusion Diagnostics Market Outlook, By Disease Screening (2021-2030) ($MN)
• Table 10 Global Blood Transfusion Diagnostics Market Outlook, By Molecular Disease Screening (2021-2030) ($MN)
• Table 11 Global Blood Transfusion Diagnostics Market Outlook, By Serological Disease Screening (2021-2030) ($MN)
• Table 12 Global Blood Transfusion Diagnostics Market Outlook, By Blood Grouping (2021-2030) ($MN)
• Table 13 Global Blood Transfusion Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 14 Global Blood Transfusion Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 15 Global Blood Transfusion Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 16 Global Blood Transfusion Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 17 Global Blood Transfusion Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 18 North America Blood Transfusion Diagnostics Market Outlook, By Country (2021-2030) ($MN)
• Table 19 North America Blood Transfusion Diagnostics Market Outlook, By Product (2021-2030) ($MN)
• Table 20 North America Blood Transfusion Diagnostics Market Outlook, By Hemoglobinometers (2021-2030) ($MN)
• Table 21 North America Blood Transfusion Diagnostics Market Outlook, By Instruments (2021-2030) ($MN)
• Table 22 North America Blood Transfusion Diagnostics Market Outlook, By Plasma (2021-2030) ($MN)
• Table 23 North America Blood Transfusion Diagnostics Market Outlook, By Reagents & kits (2021-2030) ($MN)
• Table 24 North America Blood Transfusion Diagnostics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 25 North America Blood Transfusion Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 26 North America Blood Transfusion Diagnostics Market Outlook, By Disease Screening (2021-2030) ($MN)
• Table 27 North America Blood Transfusion Diagnostics Market Outlook, By Molecular Disease Screening (2021-2030) ($MN)
• Table 28 North America Blood Transfusion Diagnostics Market Outlook, By Serological Disease Screening (2021-2030) ($MN)
• Table 29 North America Blood Transfusion Diagnostics Market Outlook, By Blood Grouping (2021-2030) ($MN)
• Table 30 North America Blood Transfusion Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 31 North America Blood Transfusion Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 32 North America Blood Transfusion Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 33 North America Blood Transfusion Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 34 North America Blood Transfusion Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 35 Europe Blood Transfusion Diagnostics Market Outlook, By Country (2021-2030) ($MN)
• Table 36 Europe Blood Transfusion Diagnostics Market Outlook, By Product (2021-2030) ($MN)
• Table 37 Europe Blood Transfusion Diagnostics Market Outlook, By Hemoglobinometers (2021-2030) ($MN)
• Table 38 Europe Blood Transfusion Diagnostics Market Outlook, By Instruments (2021-2030) ($MN)
• Table 39 Europe Blood Transfusion Diagnostics Market Outlook, By Plasma (2021-2030) ($MN)
• Table 40 Europe Blood Transfusion Diagnostics Market Outlook, By Reagents & kits (2021-2030) ($MN)
• Table 41 Europe Blood Transfusion Diagnostics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 42 Europe Blood Transfusion Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 43 Europe Blood Transfusion Diagnostics Market Outlook, By Disease Screening (2021-2030) ($MN)
• Table 44 Europe Blood Transfusion Diagnostics Market Outlook, By Molecular Disease Screening (2021-2030) ($MN)
• Table 45 Europe Blood Transfusion Diagnostics Market Outlook, By Serological Disease Screening (2021-2030) ($MN)
• Table 46 Europe Blood Transfusion Diagnostics Market Outlook, By Blood Grouping (2021-2030) ($MN)
• Table 47 Europe Blood Transfusion Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 48 Europe Blood Transfusion Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 49 Europe Blood Transfusion Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 50 Europe Blood Transfusion Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 51 Europe Blood Transfusion Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 52 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Country (2021-2030) ($MN)
• Table 53 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Product (2021-2030) ($MN)
• Table 54 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Hemoglobinometers (2021-2030) ($MN)
• Table 55 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Instruments (2021-2030) ($MN)
• Table 56 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Plasma (2021-2030) ($MN)
• Table 57 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Reagents & kits (2021-2030) ($MN)
• Table 58 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 59 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 60 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Disease Screening (2021-2030) ($MN)
• Table 61 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Molecular Disease Screening (2021-2030) ($MN)
• Table 62 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Serological Disease Screening (2021-2030) ($MN)
• Table 63 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Blood Grouping (2021-2030) ($MN)
• Table 64 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 65 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 66 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 67 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 68 Asia Pacific Blood Transfusion Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 69 South America Blood Transfusion Diagnostics Market Outlook, By Country (2021-2030) ($MN)
• Table 70 South America Blood Transfusion Diagnostics Market Outlook, By Product (2021-2030) ($MN)
• Table 71 South America Blood Transfusion Diagnostics Market Outlook, By Hemoglobinometers (2021-2030) ($MN)
• Table 72 South America Blood Transfusion Diagnostics Market Outlook, By Instruments (2021-2030) ($MN)
• Table 73 South America Blood Transfusion Diagnostics Market Outlook, By Plasma (2021-2030) ($MN)
• Table 74 South America Blood Transfusion Diagnostics Market Outlook, By Reagents & kits (2021-2030) ($MN)
• Table 75 South America Blood Transfusion Diagnostics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 76 South America Blood Transfusion Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 77 South America Blood Transfusion Diagnostics Market Outlook, By Disease Screening (2021-2030) ($MN)
• Table 78 South America Blood Transfusion Diagnostics Market Outlook, By Molecular Disease Screening (2021-2030) ($MN)
• Table 79 South America Blood Transfusion Diagnostics Market Outlook, By Serological Disease Screening (2021-2030) ($MN)
• Table 80 South America Blood Transfusion Diagnostics Market Outlook, By Blood Grouping (2021-2030) ($MN)
• Table 81 South America Blood Transfusion Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 82 South America Blood Transfusion Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 83 South America Blood Transfusion Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 84 South America Blood Transfusion Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 85 South America Blood Transfusion Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 86 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Country (2021-2030) ($MN)
• Table 87 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Product (2021-2030) ($MN)
• Table 88 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Hemoglobinometers (2021-2030) ($MN)
• Table 89 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Instruments (2021-2030) ($MN)
• Table 90 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Plasma (2021-2030) ($MN)
• Table 91 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Reagents & kits (2021-2030) ($MN)
• Table 92 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 93 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Application (2021-2030) ($MN)
• Table 94 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Disease Screening (2021-2030) ($MN)
• Table 95 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Molecular Disease Screening (2021-2030) ($MN)
• Table 96 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Serological Disease Screening (2021-2030) ($MN)
• Table 97 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Blood Grouping (2021-2030) ($MN)
• Table 98 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 99 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By End User (2021-2030) ($MN)
• Table 100 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 101 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 102 Middle East & Africa Blood Transfusion Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Blood Transfusion Diagnostics Market is accounted for $4.8 billion in 2023 and is expected to reach $8.5 billion by 2030 growing at a CAGR of 8.5% during the forecast period. This market serves a critical role in ensuring the safety and efficacy of blood transfusions by detecting infectious diseases, identifying blood groups, and assessing compatibility between donors and recipients. These diagnostics help identify potential pathogens such as HIV, hepatitis B and C, and syphilis, reducing the risk of transfusion-transmitted infections. Additionally, blood typing and crossmatching tests ensure compatibility between donor and recipient blood, minimizing the likelihood of adverse reactions during transfusions.

According to an article published by Medscape on March 2022, it was reported that the prevalence of Hemophilia A is 20.6 cases per 100,000 males in the United States. According to an article published by the Canadian Hemophilia Society (CHS) in February 2022, it was reported that the total number of Canadian suffering from Hemophilia A and B is estimated to be 3,100.

Market Dynamics:

Driver:

Rise in blood donor screening programs

With an increasing emphasis on public health and safety standards, blood donor screening programs have become more widespread, aiming to detect infectious diseases and other health conditions that could compromise the integrity of donated blood. These screening programs employ advanced diagnostic technologies such as nucleic acid testing (NAT), serological testing, and immunoassays to identify potential risks associated with donated blood, thus minimizing the chances of transfusion-transmitted infections.

Restraint:

High cost of equipment and tests

Blood transfusion diagnostics rely heavily on specialized equipment and sophisticated tests to ensure the safety and compatibility of donated blood for transfusion. These tools, ranging from automated analyzers to reagents and consumables, incur substantial expenses in procurement and maintenance. The complexity of diagnostic procedures necessitates skilled personnel for operation and interpretation, further adding to the overall costs. However, for healthcare facilities, especially in resource-constrained settings or developing countries, the financial burden of investing in such equipment and conducting tests can be prohibitive, limiting their capacity to offer comprehensive blood transfusion services.

Opportunity:

Increasing healthcare expenditure

As healthcare expenditure rises, there is a corresponding increase in the demand for advanced medical technologies and procedures, including blood transfusion diagnostics. This heightened expenditure allows healthcare facilities to invest in state-of-the-art equipment and diagnostic tools for ensuring the safety and efficacy of blood transfusions. Moreover, as healthcare budgets expand, there's greater focus on improving patient outcomes and reducing the risks associated with blood transfusions, such as transfusion-transmitted infections and adverse reactions.

Threat:

Limited access to advanced technologies

Access to cutting-edge technologies such as nucleic acid amplification tests (NAT), next-generation sequencing (NGS), and automated blood screening systems is essential for accurate and efficient blood transfusion diagnostics. In many regions, especially in developing countries or remote areas, healthcare facilities may lack the infrastructure, resources, or trained personnel to adopt these advanced technologies. As a result, the ability to perform timely and precise blood screening and compatibility testing may be compromised, leading to potential risks such as transfusion-transmitted infections or incompatible blood transfusions.

Covid-19 Impact:

The demand for blood transfusions increased due to Covid-related complications, such as severe respiratory distress or other critical conditions requiring transfusion support. This surge in demand placed pressure on diagnostic services to ensure the safety and compatibility of blood products. On the other hand, pandemic-related restrictions, fear of infection, and disruptions in healthcare services led to reduced blood donations, affecting the blood supply chain. Consequently, blood transfusion diagnostic companies faced challenges in maintaining adequate inventory levels and ensuring timely testing for donated blood, thus intensifying the need for efficient diagnostic solutions and technologies to safeguard transfusion safety amidst the pandemic's uncertainties.

The hemoglobinometers segment is expected to be the largest during the forecast period

Hemoglobinometers segment is expected to be the largest during the forecast period, as it provides quick and reliable assessments of hemoglobin concentration, aiding in the screening of blood donors and ensuring the safety and efficacy of transfusions. By enabling healthcare professionals to rapidly determine hemoglobin levels, hemoglobinometers streamline the blood donation process, reducing the risk of transfusion reactions and improving overall patient outcomes. Additionally, these devices are portable and user-friendly, making them accessible in a variety of healthcare settings, including remote or resource-limited areas.

The blood grouping segment is expected to have the highest CAGR during the forecast period

Blood Grouping segment is expected to have the highest CAGR during the forecast period. Accurate blood typing and crossmatching are critical to prevent adverse reactions during transfusions. With advancements in technology and techniques for blood grouping, such as the introduction of automated systems and molecular testing methods, healthcare facilities can efficiently determine blood types and screen for irregular antibodies. This has significantly reduced the risk of transfusion reactions and improved patient outcomes. Additionally, the increasing demand for blood products due to rising surgical procedures, trauma cases, and chronic diseases has further propelled the regional growth of the Blood Transfusion Diagnostics Market.

Region with largest share:

Over the projected period, the North American area held the largest share due to rising disposable income, improved health infrastructure, rising health consciousness, and favorable reimbursement policies. The American Red Cross estimates that 16 million blood components are transfused annually in the United States. Additionally, this region's high rate of transfusion-transmitted infections and rising blood donation awareness are predicted to fuel market expansion.

Region with highest CAGR:

Due to the rising number of patients with anemia which needs red blood cell transfusion for therapy, Asia Pacific is predicted to experience sustainable growth during the extended period, which is expected to drive up demand for blood transfusion diagnostics. Blood products and entire blood transfusions are in high demand in the area due to the rising prevalence of blood-related conditions such as hemophilia, cancer, thrombocytopenia, etc., and chronic kidney disease (CKD).

Key players in the market

Some of the key players in Blood Transfusion Diagnostics market include Abbott Laboratories, BAG Healthcare GmBH, Bio-Rad Laboratories, Inc, Danaher Corporation, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Grifols S.A., Hologic, Inc, Immucor, Inc, Ortho Clinical Diagnostics and Siemens Healthcare Private Limited.

Key Developments:

In February 2023, MedGenome Labs launched FSHD1 genetic screening test to assess the genetic changes in patients at early stages to facilitate better treatment options. Various government initiatives and approvals are also encouraging players to enter the market.

In November 2022, Werfen entered into an agreement with TPG to acquire Immucor, Inc. Immucor, Inc., is a global company with a wide range of portfolio in transfusion diagnostics products. This will help the company to widen its product range by including the specialized diagnostics solution of Immucor, Inc.

Products Covered:

• Hemoglobinometers
• Instruments
• Plasma
• Reagents & kits
• Other Products

Applications Covered:

• Disease Screening
• Blood Grouping
• Other Applications

End Users Covered:

• Diagnostic Laboratories
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Blood Transfusion Diagnostics Market, By Product

• 5.1 Introduction
• 5.2 Hemoglobinometers
• 5.3 Instruments
• 5.4 Plasma
• 5.5 Reagents & kits
• 5.6 Other Products

6 Global Blood Transfusion Diagnostics Market, By Application

• 6.1 Introduction
• 6.2 Disease Screening
  • 6.2.1 Molecular Disease Screening
  • 6.2.2 Serological Disease Screening
• 6.3 Blood Grouping
• 6.4 Other Applications

7 Global Blood Transfusion Diagnostics Market, By End User

• 7.1 Introduction
• 7.2 Diagnostic Laboratories
• 7.3 Hospitals
• 7.4 Other End Users

8 Global Blood Transfusion Diagnostics Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abbott Laboratories
• 10.2 BAG Healthcare GmBH
• 10.3 Bio-Rad Laboratories, Inc
• 10.4 Danaher Corporation
• 10.5 DiaSorin S.p.A.
• 10.6 F. Hoffmann-La Roche Ltd
• 10.7 Grifols S.A.
• 10.8 Hologic, Inc
• 10.9 Immucor, Inc
• 10.10 Ortho Clinical Diagnostics
• 10.11 Siemens Healthcare Private Limited